Prevention of the development of the side effects during using dexamethasone ( experimental study)
Abstract
World Health Organization (WHO) Director-General Tedros Adan Ghebreyesus has named dexamethasone as the only effective drug for severe cases of COVID-19. Already in June 2020, Gebreyesus called for an increase in the production of dexamethasone for the treatment of severe patients. On 2 September 2020, WHO issued an interim guideline for the use of dexamethasone based on evidence from seven clinical trials. The document contains two recommendations: WHO strongly recommends oral or intramuscular administration of corticosteroids (dexamethasone) for the treatment of patients with severe and critical COVID-19; the regimen and duration of the course is carried out once a day for 7-10 days at a dose of 6 mg.
References
World Health Organization. Coronavirus disease (COVID-19): Dexamethasone (online). 2020 [download 30.12.2020; https://www.who.int/ru/newsroom/q-a-detail/q-a-dexamethasone-and-covid-19]
Rafacho A. Dexamethasone-induced insulin resistance is associated with increased connexin 36 mRNA and protein expression in pancreatic rat islets, Canadian Journal of Physiology and Pharmacology J.R. Bosqueiro. 2007,85(5):536– 545.
Helmst dter A., Schuster N. Vaccinium myrtillus as an antidiabetic medicinal plant - Research through the ages. Pharmazie. 2010,65(5):315-21.
Council of Europe. European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes, ETS No.123 (online). 2020 [download 30.12.2020; https://www.coe.int/en/web/conventions/full-list/- /conventions/treaty/123].
RESOLUTION of the Fourth National Congress on Bioethics. (online). 2020 [download 30.12.2020; http://biomed.nas.gov.ua/files/resolution_eng.pdf]
